NetScientific PLC (AIM:NSCI) has noted first-quarter results from its portfolio company PDS Biotechnology, which also has results from key trials upcoming at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in June.
Abstract # 6041 will summarize updates to the preliminary efficacy and safety data from the PDS-sponsored VERSATILE-002 Phase 2 clinical trial, which is evaluating PDS0101 in combination with Merck's anti-PD-1 therapy KEYTRUDA for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.
Abstract # 2518 will summarize updates from last year's ASCO presentation to efficacy and survival data, as well as new findings from the ongoing National Cancer Institute (NCI)-led Triple Combination Phase 2 clinical trial.
This trial is evaluating PDS0101 in combination with two investigational immune-modulating agents across the range of HPV16-positive advanced relapsed refractory cancers.
Ilian Iliev, CEO of NetScientific, added: "Following strong progress in 2021, PDS is now approaching significant potential value inflection points, with the upcoming results of its Phase 2 trials.
PDS reported a net loss of approximately US$8.5mln, or $0.32 per basic share and diluted share, for the three months ended March 31, 2022, with net cash of US$58.9mln
“The substantial cash reserves position PDS well to navigate the biotech markets storm, as it works towards its milestones in critically important areas of the oncology therapeutics," said Iliev.